Artificial intelligence (AI)-based cancer diagnostics firm, Ibex Medical Analytics and the Research Innovation Center of Maccabi Healthcare Services has deployed Galen Gastric for detecting cancer in the gastrointestinal (GI) tract.
Gastric cancer is one of the most common malignant diseases in both men and women globally, with more than one million cases occurring every year. Pathologists, play vital roles in cancer diagnosis and detection with the assessment made to be important in making relevant treatment decisions by oncologists and enhancing the survival rates of the patients. However, a rise in the prevalence of cancer and improvement in personalized medicine have brought about the growth in the complexity of diagnostic that significantly increases the workload of pathologists. In recent years, pathology labs transition towards digital solutions, they can make use of AI-enhanced workflows to enhance the efficiency and quality of cancer diagnosis which leads to better patient care.
Ibex makes use of strong AI and machine learning technology. Its Galen platform helps pathologists to enhance the quality of cancer diagnosis, reduce the turnaround time, implement real-time quality control, and boosts productivity.
Galen Gastric is an integrated diagnostics and quality control solution that helps pathologists in detecting gastric cancer, dysplasia, H. pylori, and other vital clinical findings. The solution provided by the company is an addition to Galen Breast and Galen Prostate that Maccabi Healthcare Services have already deployed, and other labs worldwide, where they are utilized in daily practices. With the deployment, Maccabi becomes the only healthcare system globally to make use of AI for prostate and gastric biopsies, multi-tissue cancer, quality control, and efficiency and providing support to their pathologists with improved accuracy.
The director of Pathology Institute at Maccabi Healthcare Services, Judith Sandbank said: “We are glad to add Galen Gastric to be the most comprehensive AI deployment in pathology, assisting us in providing patients with the quality diagnosis. The clinical benefits from using Ibex’s AI solutions have been the main driver in the decision of Maccabi to fully adopt digital pathology, and we are impressed by how fast AI technology has become an indispensable part of our diagnostic pathway. We look forward to benefitting from its new insights in everyday practice.”
Dr. Chaim Linhart, co-founder, and CTO of Ibex added: “Galen Gastric demonstrates that our Strong AI is the leading approach for empowering pathologists with solutions that support their real-world needs. The Galen platform, recently granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA), lays the foundation for clinical-grade computational solutions that accurately identify dozens of features and become the physician’s perfect companion, helping provide every patient with an accurate, timely and personalized cancer diagnosis.”
Ibex will exhibit in the 33rd European Congress of Pathology, taking place virtually between August 29 and August 31.
